315 related articles for article (PubMed ID: 19103993)
1. Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway.
Zhu W; Soonpaa MH; Chen H; Shen W; Payne RM; Liechty EA; Caldwell RL; Shou W; Field LJ
Circulation; 2009 Jan; 119(1):99-106. PubMed ID: 19103993
[TBL] [Abstract][Full Text] [Related]
2. P53 inhibition exacerbates late-stage anthracycline cardiotoxicity.
Zhu W; Zhang W; Shou W; Field LJ
Cardiovasc Res; 2014 Jul; 103(1):81-9. PubMed ID: 24812279
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin triggers bioenergetic failure and p53 activation in mouse stem cell-derived cardiomyocytes.
Cunha-Oliveira T; Ferreira LL; Coelho AR; Deus CM; Oliveira PJ
Toxicol Appl Pharmacol; 2018 Jun; 348():1-13. PubMed ID: 29653124
[TBL] [Abstract][Full Text] [Related]
4. Concomitant low-dose doxorubicin treatment and exercise.
Sturgeon K; Schadler K; Muthukumaran G; Ding D; Bajulaiye A; Thomas NJ; Ferrari V; Ryeom S; Libonati JR
Am J Physiol Regul Integr Comp Physiol; 2014 Sep; 307(6):R685-92. PubMed ID: 25009215
[TBL] [Abstract][Full Text] [Related]
5. Rac1 signalling mediates doxorubicin-induced cardiotoxicity through both reactive oxygen species-dependent and -independent pathways.
Ma J; Wang Y; Zheng D; Wei M; Xu H; Peng T
Cardiovasc Res; 2013 Jan; 97(1):77-87. PubMed ID: 23027656
[TBL] [Abstract][Full Text] [Related]
6. Over-expression of calpastatin aggravates cardiotoxicity induced by doxorubicin.
Wang Y; Zheng D; Wei M; Ma J; Yu Y; Chen R; Lacefield JC; Xu H; Peng T
Cardiovasc Res; 2013 Jun; 98(3):381-90. PubMed ID: 23455548
[TBL] [Abstract][Full Text] [Related]
7. Serine mutations in overexpressed Hsp27 abrogate the protection against doxorubicin-induced p53-dependent cardiac apoptosis in mice.
Kanagasabai R; Karthikeyan K; Zweier JL; Ilangovan G
Am J Physiol Heart Circ Physiol; 2021 Nov; 321(5):H963-H975. PubMed ID: 34477462
[TBL] [Abstract][Full Text] [Related]
8. Astragalus polysaccharide restores autophagic flux and improves cardiomyocyte function in doxorubicin-induced cardiotoxicity.
Cao Y; Shen T; Huang X; Lin Y; Chen B; Pang J; Li G; Wang Q; Zohrabian S; Duan C; Ruan Y; Man Y; Wang S; Li J
Oncotarget; 2017 Jan; 8(3):4837-4848. PubMed ID: 27902477
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of AMPK signalling by doxorubicin: at the crossroads of the cardiac responses to energetic, oxidative, and genotoxic stress.
Gratia S; Kay L; Potenza L; Seffouh A; Novel-Chaté V; Schnebelen C; Sestili P; Schlattner U; Tokarska-Schlattner M
Cardiovasc Res; 2012 Aug; 95(3):290-9. PubMed ID: 22461523
[TBL] [Abstract][Full Text] [Related]
10. Chronic doxorubicin cardiotoxicity is mediated by oxidative DNA damage-ATM-p53-apoptosis pathway and attenuated by pitavastatin through the inhibition of Rac1 activity.
Yoshida M; Shiojima I; Ikeda H; Komuro I
J Mol Cell Cardiol; 2009 Nov; 47(5):698-705. PubMed ID: 19660469
[TBL] [Abstract][Full Text] [Related]
11. HECT-Type Ubiquitin E3 Ligase ITCH Interacts With Thioredoxin-Interacting Protein and Ameliorates Reactive Oxygen Species-Induced Cardiotoxicity.
Otaki Y; Takahashi H; Watanabe T; Funayama A; Netsu S; Honda Y; Narumi T; Kadowaki S; Hasegawa H; Honda S; Arimoto T; Shishido T; Miyamoto T; Kamata H; Nakajima O; Kubota I
J Am Heart Assoc; 2016 Jan; 5(1):. PubMed ID: 26796253
[TBL] [Abstract][Full Text] [Related]
12. Resolvin E1 protects against doxorubicin-induced cardiotoxicity by inhibiting oxidative stress, autophagy and apoptosis by targeting AKT/mTOR signaling.
Zhang J; Wang M; Ding W; Zhao M; Ye J; Xu Y; Wang Z; Ye D; Li D; Liu J; Wan J
Biochem Pharmacol; 2020 Oct; 180():114188. PubMed ID: 32750329
[TBL] [Abstract][Full Text] [Related]
13. Targeted expression of cyclin D2 ameliorates late stage anthracycline cardiotoxicity.
Zhu W; Reuter S; Field LJ
Cardiovasc Res; 2019 Apr; 115(5):960-965. PubMed ID: 30423020
[TBL] [Abstract][Full Text] [Related]
14. Levosimendan prevents doxorubicin-induced cardiotoxicity in time- and dose-dependent manner: implications for inotropy.
Efentakis P; Varela A; Chavdoula E; Sigala F; Sanoudou D; Tenta R; Gioti K; Kostomitsopoulos N; Papapetropoulos A; Tasouli A; Farmakis D; Davos CH; Klinakis A; Suter T; Cokkinos DV; Iliodromitis EK; Wenzel P; Andreadou I
Cardiovasc Res; 2020 Mar; 116(3):576-591. PubMed ID: 31228183
[TBL] [Abstract][Full Text] [Related]
15. Insulin-like growth factor II receptor-α is a novel stress-inducible contributor to cardiac damage underpinning doxorubicin-induced oxidative stress and perturbed mitochondrial autophagy.
Pandey S; Kuo WW; Shen CY; Yeh YL; Ho TJ; Chen RJ; Chang RL; Pai PY; Viswanadha VP; Huang CY; Huang CY
Am J Physiol Cell Physiol; 2019 Aug; 317(2):C235-C243. PubMed ID: 31116582
[TBL] [Abstract][Full Text] [Related]
16. p53 prevents doxorubicin cardiotoxicity independently of its prototypical tumor suppressor activities.
Li J; Wang PY; Long NA; Zhuang J; Springer DA; Zou J; Lin Y; Bleck CKE; Park JH; Kang JG; Hwang PM
Proc Natl Acad Sci U S A; 2019 Sep; 116(39):19626-19634. PubMed ID: 31488712
[TBL] [Abstract][Full Text] [Related]
17. Targeted disruption of p53 attenuates doxorubicin-induced cardiac toxicity in mice.
Shizukuda Y; Matoba S; Mian OY; Nguyen T; Hwang PM
Mol Cell Biochem; 2005 May; 273(1-2):25-32. PubMed ID: 16013437
[TBL] [Abstract][Full Text] [Related]
18. Human Amnion Membrane Proteins Prevent Doxorubicin-Induced Oxidative Stress Injury and Apoptosis in Rat H9c2 Cardiomyocytes.
Faridvand Y; Haddadi P; Vahedian V; Nozari S; Nejabati HR; Pezeshkian M; Afrasiabi A; Safaie N; Jodati A; Nouri M
Cardiovasc Toxicol; 2020 Aug; 20(4):370-379. PubMed ID: 32086724
[TBL] [Abstract][Full Text] [Related]
19. Cardiomyocyte specific ablation of p53 is not sufficient to block doxorubicin induced cardiac fibrosis and associated cytoskeletal changes.
Feridooni T; Hotchkiss A; Remley-Carr S; Saga Y; Pasumarthi KB
PLoS One; 2011; 6(7):e22801. PubMed ID: 21829519
[TBL] [Abstract][Full Text] [Related]
20. Cardioprotective roles of sestrin 1 and sestrin 2 against doxorubicin cardiotoxicity.
Li R; Huang Y; Semple I; Kim M; Zhang Z; Lee JH
Am J Physiol Heart Circ Physiol; 2019 Jul; 317(1):H39-H48. PubMed ID: 31026186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
